

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
**WO 03/080147 A1**

(51) International Patent Classification<sup>7</sup>: **A61L 31/04**,  
31/10

(21) International Application Number: **PCT/US03/08474**

(22) International Filing Date: **19 March 2003 (19.03.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
10/104,772                      20 March 2002 (20.03.2002)      **US**

(71) Applicant: **ADVANCED CARDIOVASCULAR SYSTEMS, INC.** [US/US]; 3200 Lakeside Drive, Santa Clara, CA 95052 (US).

(72) Inventors: **HOSSAINY, Syed, F., A.**; 34325 Tupelo Street, Fremont, CA 94555 (US). **DUTTA, Debashis**; 480 Oak Grove Drive, Suite 307, Santa Clara, CA 95050 (US).

(74) Agents: **KERRIGAN, Cameron et al.**; Squire, Sanders & Dempsey L.L.P., 600 Hansen Way, Palo Alto, CA 94304-1043 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 03/080147 A1**

(54) Title: **BIODEGRADABLE HYDROPHOBIC POLYMER FOR STENTS**

(57) Abstract: A stent is fabricated using a polymer that is selected for its tendency to degrade from the surface rather than undergo bulk erosion so as to substantially reduce the risk of large particles becoming detached and being swept downstream. The polymer can be hydrophobic, having water-labile linkages interconnecting the monomers. Ester or imide bonds can be incorporated in the polymer to render the material suitable for use in stent applications. The stent may be coated with the polymer or may be wholly formed therefrom.

Best Available Copy

## BIODEGRADABLE HYDROPHOBIC POLYMER FOR STENTS

## BACKGROUND OF THE INVENTION

1. Field of the invention

This invention relates to implantable medical devices such as stents. More particularly, the invention relates to materials from which a stent can be made or with which a stent can be coated.

2. Description of related art

5           In the treatment of vascular disease, such as arteriosclerosis, intracoronary stent placement is a common adjunct therapy with balloon angioplasty. Stents eliminate vasospasm, tack dissections to the vessel wall, reduce negative remodeling, and maintain the patency of the vessel. To the extent that the mechanical functionality of stents has been optimized in recent years, stents can  
10       cause some undesirable effects. For example, the continued exposure of a stent to blood can lead to thrombus formation, and the presence of a stent in a blood vessel can over time cause the blood vessel wall to weaken, which creates the potential for an arterial rupture or the formation of aneurisms. A stent can also become so overgrown by tissue after its implantation that its usefulness may be substantially  
15       decreased while its continued presence may cause a variety of problems or complications. It is therefore desirable for the stent to be biodegradable or bioabsorbable so as to diminish the adverse risks that would otherwise be associated with the stent's continued presence once its usefulness at the treatment site has ceased or has at least become substantially diminished.

5           To obviate such complications, stents can be fabricated of materials that are biodegradable or bioabsorbable. It is necessary to select a material that is both biodegradable and biocompatible, and, additionally, has suitable physical and mechanical properties necessary to properly serve its function as a stent. Such physical properties include, among others, sufficient strength to support the loads  
10   to which the stent is subjected, the radial flexibility necessary for the stent to undergo expansion, and longitudinal flexibility to allow the stent to be advanced through a contorted vasculature and to adapt to a non-linear deployment site.

          The necessary characteristics described above have been achieved with the use of polymers such as polylactic acid, copolymers of lactic acid and glycolic  
15   acid, and polycaprolactone. However, previously known biodegradable or bioabsorbable stents typically exhibit bulk erosion and are as a consequence prone to breaking-up into large particles as the matrix breaks down. The bulk erosion of such materials is likely to additionally increase if they are also used to make stent coatings, for the local delivery of drugs, thus causing the coating to flake off or  
20   otherwise become detached. Should large particles become dislodged before becoming completely degraded, they could be washed downstream and cause emboli.

          Hydrophobic polymers with water-labile linkages can serve as biodegradable or bioabsorbable materials having satisfactory resistance to bulk  
25   erosion. However, such polymers may have only a limited strength and processing capabilities. Consequently, their use has been restricted to passive devices that neither perform a structural function nor are subject to stress or distortion. The use of such polymers in stent applications has been precluded as

5 they are unable to support a lumen wall or remain attached to a stent as it undergoes deformation during its expansion.

In view of the foregoing, a biodegradable stent is therefore needed that is capable of providing the necessary structural support to a body lumen and then gradually and completely degrading or absorbing in a manner that precludes  
10 break-up into large particles. Similarly, a biodegradable coating is needed that is not prone to flaking or breaking-up into particles which may cause embolic complications.

#### SUMMARY OF THE INVENTION

15 In accordance to one embodiment of the invention, a stent made of a biologically degradable or absorbable hydrophobic polymer is provided. The polymer comprising fragments having water-labile bonds, such as ester bonds and imide bonds. The fragments having imide bonds can be derived from compounds such as trimellitylimido-L-tyrosine and 4-hydroxy-L-proline. The polymer can be  
20 a polyanhydride or a polyester. The polyanhydrides can be formed by polycondensation of one or more carboxyl-containing compounds, such as sebacic acid, di-*ortho*-carboxyphenoxy sebacate anhydride, salicylic acid, maleic acid, maleic anhydride, L-lactic acid, DL-lactic acid, L-aspartic acid, 1,3-bis-*para*-carboxyphenoxy propane, and 1,6-bis-*para*-carboxyphenoxy hexane. The  
25 polyesters can be formed by polycondensation of carboxyl-containing compounds with multifunctional alcohols or by self-polycondensation of hydroxylated organic acids. In one embodiment, the carboxyl-containing compounds can be L-lactic acid, DL-lactic acid, trimethylacetic acid, trimethylacetic acid anhydride, and butyleneterephthalate. The multifunctional alcohols are, for example, 1,10-  
30 decanediol, ethylene glycol, and 1,2,6-hexanetriol. The hydroxylated organic acid can be 4-hydroxy-L-proline. In one embodiment, the stent can comprise a

5 therapeutic substance contained by the polymer or chemically bonded to the polymer.

In accordance with another embodiment, in lieu of the stent being made from the above-described material, the stent can be coated with the material. A therapeutic substance can be incorporated into the coating. In yet another  
10 embodiment, a biologically active substance can be chemically bonded to the backbone of the polymer or incorporated into the backbone of the polymer.

In accordance with another embodiment, a stent made of or coated with a biologically degradable polymer is provided, wherein the polymer is adapted to degrade when exposed to blood to product biologically active substances, such as,  
15 for example, salicylic acid, nitric oxide, poly(ethylene glycol), heparin, heparin derivatives, hyaluronic acid, and combinations thereof.

#### DETAILED DESCRIPTION

The polymeric materials used in the embodiments of the present invention  
20 to fabricate a stent and/or a coating for a stent are selected based on strength characteristics as well as the materials' tendency to gradually erode from the surface rather than being subject to bulk erosion. Drugs or other pharmacologically or therapeutically active agents that can be incorporated within such material can be gradually released as the polymer degrades. Materials that  
25 exhibit the desired surface eroding characteristics without being subject to bulk erosion include polymers having the degradation rate higher than the rate of water penetration into the interior of the polymeric mass. Such polymers are hydrophobic as a whole but at the same time have water-labile linkages interconnecting the monomeric units comprising the polymers. As a result, the  
30 stent and/or the stent coating gradually degrades from the outermost surface inwardly, due to the slow hydrolysis of the polymers at the polymers' vulnerable

5 water-labile linkages. This process of degradation of the polymers takes place without a great risk of large particles getting dislodged.

Materials employed to fabricate the stents and/or the stent coatings of the present invention include hydrophobic polymers which have water-labile linkages interconnecting the monomeric units. The selected polymers can further include  
10 ester or imide fragments. The overall hydrophobic nature of the polymer precludes the incursion of water into the polymer's interior while the water-labile bonds that are exposed on the polymer's surface nonetheless cause the polymer to degrade. Degradation thereby progresses from the material's outermost surface inwardly to yield a uniform degradation rate and to preclude bulk erosion.

15 Using polymers having the imide or ester bonds to fabricate the stents of the present invention serves to impart sufficient strength to the material to enable the polymer to provide the support that is required of a stent. Alternatively, if the material is used to make the stent coating, the incorporation of the imide or ester fragments impart sufficient strength to the material to prevent it from flaking off  
20 or otherwise becoming detached as the underlying stent undergoes distortion cause by the radial expansion of the stent.


One of the ways to control the stent's and/or the stent coating's ultimate performance characteristics is by varying the chemical variables of the material used to fabricate the stent and/or the stent coating. For example, the number of  
25 imide or ester bonds that are incorporated in the polymer material not only affects the ultimate strength and flexibility of the stent and/or the stent coating, but also has an effect on the rate at which the material degrades when subjected to blood flow. An increased bond content enhances strength, decreases flexibility and increases degradation time.

30 Polymers that satisfy the above-described requirements include polyanhydrides and polyesters or polyorthoesters. Representative examples of polyanhydride polymers suitable for use in the construction of a stent and/or

5 fabrication of the stent coating include anhydride-co-imide terpolymers containing the following three kinds of units:

(a) units derived from trimellitylimido-L-tyrosine (TMIT), a product of acylation, via imide nitrogen, of L-tyrosine by imide of trimellitic anhydride having the formula (I)

10




(b) units derived from sebacic acid (SBA) (which is also known as decanedioic acid) having the formula  $\text{HOOC}-(\text{CH}_2)_8-\text{COOH}$ ; and

(c) units derived from 1,3-bis(*para*-carboxyphenoxy)propane (PCPP) having the formula  $\text{HOOC}-p\text{-C}_6\text{H}_4-(\text{CH}_2)_3-p\text{-C}_6\text{H}_4-\text{COOH}$ .

A general formula of this terpolymer, poly[trimellitylimido-L-tyrosine-co-sebacic acid-co-1,3-bis(*para*-carboxyphenoxy)propane], p(TMIT-SBA-PCPP), is shown below as formula (II).

20



25


In the terpolymer of formula (II) the "m" units are derived from TMIT, the "n" units from SBA, and the "o" units from PCPP. The "m" units provide the terpolymer of formula (I) with cyclic fragments having water-labile imide bonds  $-\text{N}[(\text{C}=\text{O})]_2-$ . These fragments provide the terpolymer with acidic properties because the imide anion is well stabilized via the resonance structures. For p(TMIT-SBA-PCPP) to be effective to provide sufficient strength for a stent application, a content of the imide-derived "m" units of between about 20% and about 40% (mass) can be used.

Since body fluids, such as blood, are slightly alkaline (pH ~ 7.3), the imide bonds will be hydrolyzed via  $\text{S}_{\text{N}}2$  mechanism upon contact with blood. The

35

5 rate of such nucleophilic reaction of base-catalyzed hydrolysis is low. Hence, the stent and/or the stent coating made of the terpolymer of formula (I) will be slowly degraded when exposed to blood.


Another example of a suitable polyanhydride includes a copolymer of 1,6-  
 10 bis(*para*-carboxyphenoxy)hexane (PCPX) having the formula



and di-*ortho*-carboxyphenoxy sebacate anhydride (OCPSA) having the formula



20 where the anhydride substituents of the sebacate portion of the copolymer are in the *ortho*-positions of the correspondent benzene rings. A general formula of this copolymer, p(PCPX-OCPSA) is shown below as formula (III).



In the copolymer of formula (III), the “p” units are derived from PCPX,  
 25 and the “q” units are derived from OCPSA. This copolymer is suitable for making stents and/or coatings for such stents because, as a result of biological degradation while in contact with body fluids, p(PCPX-OCPSA) releases salicylic (2-hydroxybenzoic) acid (SA). SA having the formula HO-*ortho*-C<sub>6</sub>H<sub>4</sub>-COOH is an antiplatelet agent.

30 Another example of a suitable polyanhydride includes poly(maleic acid-co-sebacic acid), p(MA-SBA), synthesized from maleic acid (MA) having the formula HOOC-CH=CH-COOH or anhydride thereof, and sebacic acid or anhydride thereof.



5           Another example of a suitable polyanhydride includes terpolymers including the units derived from PCPP, SBA and SA. This terpolymer, poly[1,3-bis(*para*-carboxyphenoxy) propane-co-sebacic acid-co-salicylic acid], p(PCPP-SBA-SA), is similar to p(TMIT-SBA-PCPP) shown by formula II, except that trimellitylimido-L-tyrosine units are substituted with salicylic acid units. Thus, in  
10   p(PCPP-SBA-SA), units derived from salicylic acid constitute a part of the backbone of the copolymer. Consequently, SA is released upon biological degradation of p(PCPP-SBA-SA).

          Yet other examples of a suitable polyanhydride include poly(L-lactic acid), pLLA, poly(DL-lactic acid), pDLLA, and products of polycondensation of L- or  
15   DL-lactic acid with other multifunctional acids.

          Examples of such products of polycondensation include poly(L-lactic acid-co-L-aspartic acid), p(LLA-LAspA), or poly(DL-lactic acid-co-L-aspartic acid), p(DLLA-LAspA). p(LLA-LAspA) or p(DLLA-LAspA) can be synthesized from  
20   either L- or DL- optical isomer of lactic acid,  $\text{CH}_3\text{-CH(OH)-COOH}$ , (LLA and DLLA, respectively) and L-aspartic acid (LAspA), also known as aminosuccinic acid, or 1-amino-1,2-dicarboxyethane, which is an amino acid having the formula  $\text{HOOC-CH}_2\text{-CH(NH}_2\text{)-COOH}$ .

          Polyesters are another class of biologically degradable polymers suitable for making stents and/or stent coatings. Polyesters contain fragments with ester  
25   bonds which are water-labile bonds, similar to that of imide bonds. When contact with slightly alkaline blood these bonds are subject to catalyzed hydrolysis, thus ensuring biological degradability of the polyester. Representative examples of polyester polymers suitable for use in the construction of a stent and/or fabrication of the stent coating include poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate)

5 (PHV), and poly(hydroxybutyrate-valerate) (PHBV), which is copolymer of hydroxybutyrate and hydroxyvalerate, as well as poly(4-hydroxy-L-proline ester), p(HOXPE) which is a product of self-polycondensation of 4-hydroxy-L-proline (HOXP). HOXP having an imide bond provides p(HOXPE) with fragments comprising both ester bonds and imide bonds. As a result, the biological  
10 degradation of p(HOXPE) is facilitated.

Other examples of polyesters suitable for making a stent and/or a stent coating include, poly(1,10-decanediol-1,10-decanediol dilactide), p(DCD-LLA) or p(DCD-DLLA), which is a product of polycondensation of a relatively long-chained glycol, 1,10-decanediol (DCD) and either L- or DL-lactic acid, LLA or  
15 DLLA, respectively.

Another example of a suitable polyorthoester that can be used to make stents and/or stent coatings is a block-copolymer of either LLA or DLLA with ethylene glycol (EG). Such block-copolymer, poly[L-(or DL-) lactic acid-co-ethylene glycol], p(LLA-EG) or p(DLLA-EG), comprising units derived from EG  
20 and from lactic acid (either L- or DL- optical isomer, as the case may be), can be synthesized by polymerization of LLA or DLLA induced by the poly(ethylene glycol) (PEG) macroinitiator.

While in contact with the body fluids, p(LLA-EG) or p(DLLA-EG) degrades to yield monomeric lactic acid and PEG. Both of these products are  
25 biologically compatible, and PEG also has an additional advantage of being biologically active, reducing smooth muscle cells proliferation at the lesion site and thus capable of inhibiting restenosis.

Another example of the PEG-containing polyester, suitable for making a stent and/or a stent coating in accordance with the present invention includes a

5 block-copolymer of EG with butyleneterephthalate (BT). This block-copolymer can be obtained, for example, by trans-esterification of dibutylterephthalate with PEG.

Yet another example of a polyester suitable making a stent and/or a stent coating in accordance with the present invention includes poly(1,2,6-hexanetriol-  
10 trimethylorthoacetate), p(HTOL-TMAC), a product of polycondensation of a trifunctional alcohol 1,2,6-hexanetriol (HTOL) and trimethylacetic acid.

For any of the polyester polymers described above, a content of ester-derived units of between about 20% and about 40% (mass) is effective to provide sufficient strength for a stent application.

15 Table 1 presents the summary of these polymers and also shows the monomers used to synthesize the polymers.

5 Table 1. Polymers Usable for Fabrication of Biodegradable Stents And/Or Stent Coatings

No.	Polymer and abbreviation	Monomer 1 and abbreviation	Monomer 2 and abbreviation	Monomer 3 and abbreviation
1	Poly[trimellitylimido-L-tyrosine-co-sebacic acid-co-1,3-bis( <i>para</i> -carboxyphenoxy)propane], p(TMIT-SBA-PCPP)	Trimellitylimido-L-tyrosine (TMIT)	Sebacic acid (SBA)	1,3-bis ( <i>para</i> -carboxyphenoxy)propane (PCPP)
2	Poly[1,6-bis( <i>para</i> -carboxyphenoxy)hexane-co-di-o-carboxyphenoxy sebacate anhydride], p(PCPX-OCPSA)	1,6-bis ( <i>para</i> -carboxyphenoxy)hexane (PCPX)	di- <i>ortho</i> -carboxyphenoxy sebacate anhydride (OCPSA)	None
3	Poly[1,3-bis( <i>para</i> -carboxyphenoxy)propane-co-salicylic acid-co-sebacic acid], p(PCPP-SBA-SA)	1,3-bis( <i>para</i> -carboxyphenoxy)propane (PCPP)	Sebacic acid or anhydride (SBA)	Salicylic acid (SA)
4	Poly(maleic acid-co-sebacic acid), p(MA-SBA)	Maleic acid (MA)	Sebacic acid or anhydride (SBA)	None
5	Poly(L-lactic acid-co-L-aspartic acid), p(LLA-LAspA)	L-lactic acid (LLA)	L-aspartic acid (LAspA)	None
6	Poly(DL-lactic acid-co-L-aspartic acid), p(DLLA-LAspA)	DL-lactic acid (DLLA)	L-aspartic acid (LAspA)	None
7	Poly(L-lactic acid), pLLA	L-lactic acid (LLA)	None	None
8	Poly(DL-lactic acid), pDLLA	DL-lactic acid (DLLA)	None	None
9	Poly(L-lactic acid-co-ethylene glycol), p(LLA-EG)	L-lactic acid (LLA)	Ethylene glycol (EG)	None
10	Poly(DL-lactic acid-co-ethylene glycol), p(DLLA-EG)	DL-lactic acid (DLLA)	Ethylene glycol (EG)	None
11	Poly(ethylene glycol-co-butyleneterephthalate), p(EG-BT)	Ethylene glycol (EG)	Butyleneterephthalate (BT)	None
12	Poly(4-hydroxy-L-proline ester), p(HOXPE)	4-hydroxy-L-proline (HOXP)	None	None

13	Poly(1,10-decanediol-1,10-decanediol dilactide), p(DCD-LLA)	1,10-decanediol (DCD)	L-lactic acid (LLA)	None
14	Poly(1,10-decanediol-1,10-decanediol dilactide), p(DCD-DLLA)	1,10-decanediol (DCD)	DL-lactic acid (DLLA)	None
15	Poly(1,2,6-hexanetriol-trimethyl orthoacetate), p(HTOL-TMAC)	1,2,6-hexanetriol (HTOL)	Trimethylacetic acid(anhydride) (TMAC)	None
16	Poly(hydroxybutyrate) (PHB)	Hydroxybutyrate (HB)	None	None
17	Poly(hydroxyvalerate) (PHV)	Hydroxyvalerate (HV)	None	None
18	Poly(hydroxy-butyrate-valerate) (PHBV)	Hydroxybutyrate (HB)	Hydroxyvalerate (HV)	N/A

5 A stent of the present invention can be formed by first causing the appropriate reagents to react to form the desired polyanhydride or polyester composition. During copolymer synthesis, the imide content of such composition is increased by incorporating higher imide-containing monomers like trimellitylimido-L-tyrosine. Increasing imide content results in higher material strength. The ester  
10 content of such composition is increased by incorporating higher ester containing monomers such as L-proline ester or trimethyl orthoacetate. Flexibility of polyanhydrides like p(MA-SBA) can be increased by increasing the percentage of maleic acid dimer (MAD) during polymer synthesis.

Therapeutically active agents can be optionally added to the reagents so as  
15 to incorporate such agents throughout the polymer to thereby provide for the gradual dispensation of the agent over the service life of the matrix. The blending may be accomplished either in solution or in a melt state. Alternatively, some active agents may be infused throughout the polymer after polymerization is completed. Some active agents can be chemically incorporated into the backbone  
20 of the polymer, or can be chemically bonded to the polymer backbone as a pendant group. One example of such an active agent is salicylic acid. Other examples of active agents that can be chemically incorporated into the polymer include nitric oxide, PEG, heparin and its derivatives, and hyaluronic acid.

The therapeutically active agent can include any substance capable of  
25 exerting a therapeutic or prophylactic effect in the practice of the present invention. The agent may include small or large molecule drugs, peptides, proteins, oligonucleotides, or DNA. Examples include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof. Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I<sub>1</sub>,  
30 actinomycin X<sub>1</sub>, and actinomycin C<sub>1</sub>. The active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances.

5 Examples of such antineoplastics and/or antimitotics include paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride, and mitomycin. Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, heparin derivatives having hydrophobic counter ions,  
10 hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin. Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme  
15 inhibitors such as captopril, cilazapril or lisinopril, calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil ( $\omega$ -3- fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside,  
20 phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permiroblast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, rapamycin and its  
25 derivatives (one example of which is everolimus available from Novartis Corp.), and dexamethasone.

Although the embodiments of the present invention have been described with reference to a stent, such as a balloon expandable or self-expandable stent, other implantable medical devices can also be made from or coated with the  
30 polymers. Examples of the implantable medical device include stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, coronary shunts and endocardial leads (e.g., FINELINE and

5    ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be of virtually any design.

          The stent may be formed by any of a number of well known methods including the extrusion of the polymer into the shape of a tube. Pre-selected patterns of voids can then be formed into the tube in order to define a plurality of  
10    spines or struts that impart a degree of flexibility and expandability to the tube. Alternatively, the drug loaded polymer may be applied to the selected surfaces of a stent made of, for example, stainless steel. The stent can be, for example, immersed in the molten polymer or sprayed with a liquid form of the polymer. In yet another exemplary embodiment, the polymer may be extruded in the form of a  
15    tube which is then co-drawn with a tube of stainless steel, or other suitable metallic materials or alloys. By co-drawing two tubes of the polymer with the metal tube, one positioned about the exterior of the metal tube and another positioned within the metal tube, a tube having multi-layered walls is formed. Subsequent perforation of the tube walls to define a pre-selected pattern of spines  
20    or struts imparts the desired flexibility and expandability to the tube to create a stent.

          The polymer listed in Table 1 can be further blended or coated with one or a plurality of other polymers, referred to herein as "alternative polymers." One example of an alternative polymer is poly(ethylene-co-vinyl alcohol), also known  
25    under the trade name EVAL and distributed commercially by Aldrich Chemical Company of Milwaukee, Wisconsin. EVAL is also manufactured by EVAL Company of America, Lisle, Illinois. EVAL is a product of hydrolysis of ethylene-vinyl acetate copolymers. EVAL may also be a terpolymer and may include up to 5% (molar) of units derived from styrene, propylene and other  
30    suitable unsaturated monomers.



5           Other examples of alternative polymers include poly(hydroxyvalerate),  
polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate),  
poly(hydroxybutyrate-co-valerate), polydioxanone, poly(glycolic acid),  
polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates,  
poly(iminocarbonate), copoly(ether-esters) (e.g. PEO/PLA), polyalkylene  
10 oxalates, polyphosphazenes, polyurethanes, silicones, polyolefins,,  
polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and  
copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride,  
polyvinyl ethers, such as polyvinyl methyl ether, polyvinylidene halides, such as  
polyvinylidene fluoride and polyvinylidene chloride, polyacrylonitrile, polyvinyl  
15 ketones, polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as  
polyvinyl acetate, copolymers of vinyl monomers with each other and olefins,  
such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene  
copolymers, ABS resins, and ethylene-vinyl acetate copolymers, polyamides, such  
as Nylon 66 and polycaprolactam, alkyd resins, polycarbonates,  
20 polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, rayon,  
rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate  
butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers,  
carboxymethyl cellulose, and biomolecules, such as fibrin, fibrinogen, cellulose,  
starch, collagen and hyaluronic acid.

25

The following examples are provided for illustrative purposes.

#### Example 1

A first composition can be prepared by mixing the following components:

- (a) between about 0.1 mass % and about 15 mass %, for example, about  
30 1.0 mass % of p(LLA-EG);

5           (b) between about 0.1 mass % and about 10.0 mass %, for example, about 2.0 mass % of p(DLLA);

          (c) between about 0.05 mass % and about 2.0 mass %, for example, about 1.0 mass % of a biologically active substance such as rapamycin, or a derivative or analog thereof; and

10          (d) the balance, dioxane solvent.

          The first composition is applied onto the stent and dried to form a drug-polymer layer. The composition is applied onto the stent by any conventional method, for example, by spraying or dipping. A primer layer (e.g., the above formulation without the therapeutically active substance) can be optionally  
15       applied on the surface of the bare stent prior to the application of the drug-polymer layer.

          For a stent having a length of 13 mm and diameter of 3 mm, the total amount of solids of the matrix layer can be about 300 micrograms (corresponding to the thickness of between about 15 and 20 microns). "Solids" means the amount  
20       of the dry residue deposited on the stent after all volatile organic compounds (e.g., the solvent) have been removed.

          A second composition can be prepared by mixing the following components:

          (a) between about 0.1 mass % and about 15 mass %, for example, about  
25       1.0 mass % of p(LLA-EG);

          (b) between about 0.1 mass % and about 10.0 mass %, for example, about 2.0 mass % of p(DLLA); and

          (c) the balance, dioxane solvent.

5           The second composition is applied onto the dried drug-polymer layer and dried, to form an optional topcoat layer. The topcoat layer can be applied by any conventional method and can have, for example, a total solids weight of about 200  $\mu\text{g}$ .

A third composition can be prepared by mixing the following components:

10           (a) between about 0.1 mass % and about 15 mass %, for example, about 1.125 mass % of p(LLA-EG);

(b) between about 0.1 mass % and about 10.0 mass %, for example, about 0.75 mass % of p(DLLA); and

(c) the balance, dioxane solvent.

15           The third composition is applied onto the topcoat layer and dried, to form an optional finishing coat layer. The finishing coat layer can be applied by any conventional method and can have, for example, a total solids weight of about 150  $\mu\text{g}$ .

#### Example 2

20           A first composition can be prepared by mixing the following components:

(a) between about 0.1 mass % and about 15 mass %, for example, about 1.0 mass % of p(LLA-EG);

(b) between about 0.1 mass % and about 10.0 mass %, for example, about 2.0 mass % of p(DLLA);

25           (c) between about 0.05 mass % and about 2.0 mass %, for example, about 1.0 mass % of estradiol; and

- 5 (d) the balance, dioxane solvent.

The first composition is applied onto a stent to form a drug-polymer layer with about 300  $\mu\text{g}$  of total solids.

A second composition can be prepared by mixing the following components:

- 10 (a) between about 0.1 mass % and about 15 mass %, for example, about 1.0 mass % of p(LLA-EG);

(b) between about 0.1 mass % and about 10.0 mass %, for example, about 2.0 mass % of p(DLLA); and

- (c) the balance, dioxane solvent.

- 15 The second composition is applied onto the dried drug-polymer layer and dried to form an optional topcoat layer. The topcoat layer can have, for example, a total solids weight of about 200  $\mu\text{g}$ .

A third composition can be prepared by mixing the following components:

- (a) between about 0.1 mass % and about 15 mass %, for example, about  
20 1.125 mass % of p(LLA-EG);

(b) between about 0.1 mass % and about 10.0 mass %, for example, about 0.75 mass % of p(DLLA); and

- (c) the balance, dioxane solvent.

- 25 The third composition is applied onto the topcoat layer and dried, to form the optional finishing coat layer. The finishing coat layer can have, for example, a total solids weight of about 150  $\mu\text{g}$ .

5

Example 3

A first composition can be prepared by mixing the following components:

(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of p(PCPP-SA-SBA);

(b) between about 0.05 mass % and about 2.0 mass %, for example, about 1.0 mass % of estradiol; and

(c) the balance, a solvent mixture containing about equal mass amounts of dimethylacetamide (DMAC) and tetrahydrofuran (THF).

The first composition is applied onto a stent to form a drug-polymer layer with about 300 µg of total solids.

15 A second composition can be prepared by mixing the following components:

(a) between about 0.1 mass % and about 15 mass %, for example, about 2.0 mass % of p(PCPP-SA-SBA); and

(c) the balance, a solvent mixture containing about equal mass amounts of DMAC and THF.

The second composition is applied onto the dried drug-polymer layer to form an optional topcoat layer. The topcoat layer can have, for example, a total solids weight of about 200 µg.

The three examples of the formulations above can be summarized as shown in Table 2.

5           While particular embodiments of the present invention have been shown  
and described, it will be obvious to those skilled in the art that changes and  
modifications can be made without departing from this invention in its broader  
aspects. Therefore, the appended claims are to encompass within their scope all  
such changes and modifications as fall within the true spirit and scope of this  
10 invention.

Table 2. A Summary of the Formulations of Examples 1-3

Example	Polymer in matrix layer	Drug in matrix layer	Solids in dry matrix layer, $\mu\text{g}$	Polymer in topcoat layer	Solids in the dry topcoat layer, $\mu\text{g}$	Polymer in finishing layer	Solids in the dry finishing layer, $\mu\text{g}$
1	p(LLA-EG), 1% and p(DLLA), 2%	a derivative of rapamycin, 1.0%	300	p(LLA-EG), 1% and p(DLLA), 2%	200	p(LLA-EG), 1.125% and p(DLLA), 0.75%	150
2	p(LLA-EG), 1% and p(DLLA), 2%	estradiol, 1.0%	300	p(LLA-EG), 1% and p(DLLA), 2%	200	p(LLA-EG), 1.125% and p(DLLA), 0.75%	150
3	p(PCPP-SA-SBA), 2%	estradiol, 1.0%	300	p(PCPP-SA-SBA), 2%	200	None	N/A

## 5 CLAIMS

## WHAT IS CLAIMED IS:

1. A stent made of a biologically degradable or absorbable hydrophobic polymer, the polymer comprising fragments having water-labile bonds.
- 10 2. The stent of Claim 1, wherein the water-labile bonds comprise ester bonds and imide bonds.
3. The stent of Claim 2, wherein the fragments having imide bonds are  
15 derived from compounds selected from a group consisting of trimellitylimido-L-tyrosine and 4-hydroxy-L-proline.
4. The stent of Claim 1, wherein the polymer is selected from a group consisting of polyanhydrides and polyesters.
- 20 5. The stent of Claim 4, wherein the polyanhydrides are formed by polycondensation of one or more carboxyl-containing compounds.
6. The stent of Claim 5, wherein the carboxyl-containing compounds are  
25 selected from a group consisting of sebacic acid, di-*ortho*-carboxyphenoxy sebacate anhydride, salicylic acid, maleic acid, maleic anhydride, L-lactic acid, DL-lactic acid, L-aspartic acid, 1,3-bis-*para*-carboxyphenoxy propane, and 1,6-bis-*para*-carboxyphenoxy hexane.
- 30 7. The stent of Claim 4, wherein the polyesters are formed by polycondensation of carboxyl-containing compounds with multifunctional alcohols or by self-polycondensation of hydroxylated organic acids.



- 5     8.     The stent of Claim 7, wherein the carboxyl-containing compounds are selected from a group consisting of L-lactic acid, DL-lactic acid, trimethylacetic acid, trimethylacetic acid anhydride, and butyleneterephthalate.
9.     The stent of Claim 7, wherein the multifunctional alcohols are selected  
10    from a group consisting of 1,10-decanediol, ethylene glycol, and 1,2,6-hexanetriol.
10.    The stent of Claim 7, wherein the hydroxylated organic acid is 4-hydroxy-L-proline.
- 15    11.    The stent of Claim 7, wherein the polyesters are selected from a group consisting of poly(hydroxybutyrate), poly(hydroxyvalerate), and poly(hydroxybutyrate-valerate).
12.    The stent of Claim 1, further comprising a therapeutic substance contained  
20    by the polymer or chemically bonded to the polymer.
13.    A stent comprising a coating including a biologically degradable or absorbable hydrophobic polymer, wherein the polymer comprises fragments having water-labile bonds.
- 25    14.    The stent of Claim 13, wherein the water-labile bonds comprise ester bonds and imide bonds.
15.    The stent of Claim 14, wherein the fragments having imide bonds are  
30    derived from compounds selected from a group consisting of trimellitylimido-L-tyrosine and 4-hydroxy-L-proline.

- 5     16.     The stent of Claim 13, wherein the polymer is selected from a group consisting of polyanhydrides and polyesters.
17.     The stent of Claim 16, wherein the polyanhydrides are formed by polycondensation of one or more carboxyl-containing compounds.
- 10
18.     The stent of Claim 17, wherein the carboxyl-containing compounds are selected from a group consisting of sebacic acid, di-*ortho*-carboxyphenoxy sebacate anhydride, salicylic acid, maleic acid, L-lactic acid, DL-lactic acid, L-aspartic acid, 1,3-bis-*para*-carboxyphenoxy propane, and 1,6-bis-*para*-
- 15     carboxyphenoxy hexane.
19.     The stent of Claim 16, wherein the polyesters are formed by polycondensation of carboxyl-containing compounds with multifunctional alcohols or by self-polycondensation of hydroxylated organic acids.
- 20
20.     The stent of Claim 19, wherein the carboxyl-containing compounds are selected from a group consisting of L-lactic acid, DL-lactic acid, trimethylacetic acid, anhydride of trimethylacetic acid, and butyleneterephthalate.
- 25     21.     The stent of Claim 19, wherein the multifunctional alcohols are selected from a group consisting of 1,10-decanediol, ethylene glycol, and 1,2,6-hexanetriol.
22.     The stent of Claim 19, wherein the hydroxylated organic acid is 4-hydroxy-L-proline.
- 30

- 5    23.    The stent of Claim 19, wherein the polyesters are selected from a group  
consisting of poly(hydroxybutyrate), poly(hydroxyvalerate), and  
poly(hydroxybutyrate-valerate).
24.    The stent of Claim 13, further comprising a therapeutic substance  
10    incorporated into the coating.
25.    The stent of Claim 13, further comprising a biologically active substance  
chemically bonded to the backbone of the polymer or incorporated into the  
backbone of the polymer.
- 15    26.    A stent made of or coated with a biologically degradable polymer, the  
polymer adapted to degrade when exposed to blood, wherein products of  
degradation of the polymer include biologically active substances.
- 20    27.    The stent of Claim 26, wherein the biologically active substances are  
salicylic acid, nitric oxide, poly(ethylene glycol), heparin, heparin derivatives,  
hyaluronic acid, and combinations thereof.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/08474

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L31/04 A61L31/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 74744 A (AMERICAN MED SYST ;JADHAV BALKRISHNA S (US)) 14 December 2000 (2000-12-14)  page 4, line 14 - line 31 page 7, line 4 - line 9 page 8, line 14 - line 34 claims 1,2	1,2,4-8, 11,13, 14, 16-20, 23-27
X	WO 00 44309 A (UNIV TEXAS) 3 August 2000 (2000-08-03)  page 3, line 3 - line 10 page 5, line 30 -page 6, line 24 claims 1-13	1,2,4-8, 11,13, 14, 16-20, 23-27
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*8\* document member of the same patent family

Date of the actual completion of the international search

11 July 2003

Date of mailing of the international search report

23/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Menidjel, R

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 03/08474

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 99 34750 A (BIOAMIDE INC ; BARROWS THOMAS H (US)) 15 July 1999 (1999-07-15)</p> <p>page 3, line 3 - line 10 page 5, line 30 - page 6, line 24 claims 1-13</p>	<p>1,2,4-8, 11-14, 16-20, 23-27</p>
X	<p>US 6 071 266 A (KELLEY DONALD W) 6 June 2000 (2000-06-06)</p> <p>column 1, line 7 - line 30 column 2, line 6 - line 9 claims 1-10</p>	<p>1,2,4-7, 12-14, 16-19, 24-27</p>

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/08474

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0074744	A	14-12-2000	US 6368346 B1	09-04-2002
			AU 5463100 A	28-12-2000
			CA 2375737 A1	14-12-2000
			EP 1185317 A1	13-03-2002
			WO 0074744 A1	14-12-2000
			US 2001029398 A1	11-10-2001
WO 0044309	A	03-08-2000	AU 3220100 A	18-08-2000
			BR 0007932 A	02-07-2002
			CA 2360168 A1	03-08-2000
			EP 1148839 A2	31-10-2001
			JP 2002535076 T	22-10-2002
			WO 0044309 A2	03-08-2000
			US 6409750 B1	25-06-2002
WO 9934750	A	15-07-1999	AU 734539 B2	14-06-2001
			AU 2106499 A	26-07-1999
			CA 2314963 A1	15-07-1999
			EP 1045677 A1	25-10-2000
			JP 2002500065 T	08-01-2002
			WO 9934750 A1	15-07-1999
			US 6511748 B1	28-01-2003
US 6071266	A	06-06-2000	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**